Manas AI is a disruptive drug development AI firm that offers drugs for cancer and rare diseases.
Manas AI has raised $24.6M in total funding. The most recent round was Seed. The last funding was announced in January 2025.
Manas AI's investors include General Catalyst, Greylock, Reid Hoffman.
Manas AI is headquartered in San Francisco, United States.
Manas AI is a disruptive drug development AI firm that offers drugs for cancer and rare diseases.
Manas AI is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Manas AI — Funding & Investors." VCBacked, January 27, 2025, https://www.vcbacked.co/company/manas-ai. Accessed September 13, 2026.
VCBacked. (2025). Manas AI — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/manas-ai
{{cite web |title=Manas AI — Funding & Investors |url=https://www.vcbacked.co/company/manas-ai |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated